Chularat Hospital Public Company Limited and its subsidiaries Review report and interim financial information For the three-month and six-month periods ended 30 June 2022 Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Chularat Hospital Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Chularat Hospital Public Company Limited and its subsidiaries as at 30 June 2022, the related consolidated statements

of comprehensive income for the three-month and six-month periods then ended, and the related

consolidated statements of changes in shareholders' equity and cash flows for the six-month period

then ended, as well as the condensed notes to the interim consolidated financial statements. I have

also reviewed the separate financial information of Chularat Hospital Public Company Limited for the

same periods (collectively "interim financial information"). Management is responsible for the

preparation and presentation of this interim financial information in accordance with Thai Accounting

Standard 34 Interim Financial Reporting. My responsibility is to express a conclusion on this interim

financial information based on my review.

Scope of Review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, Review

of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of

interim financial information consists of making inquiries, primarily of persons responsible for

financial and accounting matters, and applying analytical and other review procedures. A review

is substantially less in scope than an audit conducted in accordance with Thai Standards on

Auditing and consequently does not enable me to obtain assurance that I would become aware of

all significant matters that might be identified in an audit. Accordingly, I do not express an audit

opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the

accompanying interim financial information is not prepared, in all material respects, in accordance

with Thai Accounting Standard 34 Interim Financial Reporting.

Kosum Cha-em

Certified Public Accountant (Thailand) No. 6011

EY Office Limited

Bangkok: 11 August 2022

Chularat Hospital Public Company Limited and its subsidiaries Statement of financial position

As at 30 June 2022

(Unit: Thousand Baht)

		Consolidated fin	ancial statements	Separate financial statements		
	Note	30 June 2022	31 December 2021	30 June 2022	31 December 2021	
		(Unaudited	(Audited)	(Unaudited	(Audited)	
		but reviewed)		but reviewed)		
Assets						
Current assets						
Cash and cash equivalents		1,281,429	2,789,666	430,868	781,074	
Trade and other receivables	3	704,226	616,282	466,124	544,953	
Accrued medical treatment income	4	3,502,793	1,820,524	1,436,622	775,854	
Inventories		315,432	295,095	171,611	149,496	
Other current assets		89,151	375,615	13,746	210,977	
Total current assets	•	5,893,031	5,897,182	2,518,971	2,462,354	
Non-current assets	•					
Restricted bank deposits		607	607	-	-	
Long-term loans to related parties	2	-	-	365,974	502,474	
Other non-current financial assets		-	-	-	-	
Investments in subsidiaries	5	-	-	2,204,290	2,204,290	
Investment properties		75,654	75,654	298	298	
Property, plant and equipment		4,358,662	4,286,301	1,275,431	1,245,203	
Right-of-use assets		79,370	72,076	22,349	21,169	
Intangible assets		34,392	34,465	21,271	21,660	
Goodwill		47,284	47,284	-	-	
Deferred tax assets		26,126	25,149	14,022	13,464	
Other non-current assets		130,860	110,969	16,257	14,533	
Total non-current assets	-	4,752,955	4,652,505	3,919,892	4,023,091	
Total assets	-	10,645,986	10,549,687	6,438,863	6,485,445	

Chularat Hospital Public Company Limited and its subsidiaries Statement of financial position (continued)

As at 30 June 2022

(Unit: Thousand Baht)

		Consolidated fin	ancial statements	Separate financial statements		
	Note	30 June 2022	31 December 2021	30 June 2022	31 December 2021	
		(Unaudited	(Audited)	(Unaudited	(Audited)	
		but reviewed)		but reviewed)		
Liabilities and shareholders' equity						
Current liabilities						
Short-term loans from financial institutions	6	21,000	34,000	-	-	
Trade and other payables		806,127	842,172	371,830	357,981	
Current portion of long-term loans from						
financial institutions	7	64,997	97,058	-	-	
Current portion of lease liabilities		23,260	19,670	6,369	3,988	
Income tax payable		522,463	729,238	220,898	342,900	
Other current liabilities		438,752	486,161	204,632	458,763	
Total current liabilities		1,876,599	2,208,299	803,729	1,163,632	
Non-current liabilities	•					
Long-term loans from financial institutions						
- net of current portion	7	269,734	313,489	-	-	
Lease liabilities, net of current portion		52,151	49,867	17,787	19,348	
Derivatives liabilities		39,387	870	-	-	
Deferred tax liabilities		10,829	10,868	-	-	
Provision for long-term employee benefits		126,833	121,350	67,422	64,273	
Other non-current liabilities		6,908	3,980	-	-	
Total non-current liabilities		505,842	500,424	85,209	83,621	
Total liabilities		2,382,441	2,708,723	888,938	1,247,253	
	•					

Chularat Hospital Public Company Limited and its subsidiaries Statement of financial position (continued)

As at 30 June 2022

(Unit: Thousand Baht)

	Consolidated fin	ancial statements	Separate financial statements		
	30 June 2022	31 December 2021	30 June 2022	31 December 2021	
	(Unaudited	(Audited)	(Unaudited	(Audited)	
	but reviewed)		but reviewed)		
Shareholders' equity					
Share capital					
Registered					
11,000,000,000 ordinary shares					
of Baht 0.1 each	1,100,000	1,100,000	1,100,000	1,100,000	
Issued and fully paid					
11,000,000,000 ordinary shares					
of Baht 0.1 each	1,100,000	1,100,000	1,100,000	1,100,000	
Share premium	1,146,085	1,146,085	1,146,085	1,146,085	
Retained earnings					
Appropriated - statutory reserve	110,000	110,000	110,000	110,000	
Unappropriated	5,577,489	5,212,855	3,193,840	2,882,107	
Equity attributable to owners of the Company	7,933,574	7,568,940	5,549,925	5,238,192	
Non-controlling interests of the subsidiaries	329,971	272,024	-	-	
Total shareholders' equity	8,263,545	7,840,964	5,549,925	5,238,192	
Total liabilities and shareholders' equity	10,645,986	10,549,687	6,438,863	6,485,445	

Directors

Statement of comprehensive income

For the three-month period ended 30 June 2022

(Unit: Thousand Baht, except earnings per share expressed in Baht)

		Consolidated finan	cial statements	Separate financial statements	
	Note	2022	2021	2022	2021
Profit or loss:					
Revenues					
Revenues from hospital operations		2,784,491	2,071,014	1,118,558	909,572
Dividend income	5	-	-	1,220,000	120,000
Other income		68,100	63,997	2,977	1,461
Total revenues		2,852,591	2,135,011	2,341,535	1,031,033
Expenses					
Cost of hospital operations		1,496,982	1,206,095	610,799	477,633
Administrative expenses		223,121	205,787	112,062	111,828
Total expenses		1,720,103	1,411,882	722,861	589,461
Operating profit		1,132,488	723,129	1,618,674	441,572
Finance income		3,332	555	5,261	6,400
Finance cost		(3,110)	(5,189)	(248)	(1,255)
Profit before income tax expenses		1,132,710	718,495	1,623,687	446,717
Income tax expenses		(225,637)	(143,184)	(79,965)	(64,492)
Profit for the period		907,073	575,311	1,543,722	382,225
Other comprehensive income:					
Other comprehensive income for the period			-		
Total comprehensive income for the period		907,073	575,311	1,543,722	382,225

Statement of comprehensive income (continued)

For the three-month period ended 30 June 2022

(Unit: Thousand Baht, except earnings per share expressed in Baht)

	Consolidated fina	incial statements	Separate financial statements		
	2022	2021	2022	2021	
Profit (loss) attributable to:					
Equity holders of the Company	878,235	576,081	1,543,722	382,225	
Non-controlling interests of the subsidiaries (loss)	28,838	(770)			
	907,073	575,311			
Total comprehensive income attributable to:					
Equity holders of the Company	878,235	576,081	1,543,722	382,225	
Non-controlling interests of the subsidiaries (loss)	28,838	(770)			
	907,073	575,311			
Basic earnings per share					
Profit attributable to equity holders of the Company					
(Baht per share)	0.0798	0.0524	0.1403	0.0347	
Weighted average number of ordinary shares					
(Thousand shares)	11,000,000	11,000,000	11,000,000	11,000,000	

Statement of comprehensive income

For the six-month period ended 30 June 2022

(Unit: Thousand Baht, except earnings per share expressed in Baht)

		Consolidated fina	ncial statements	Separate financial statements	
	Note	2022	2021	2022	2021
Profit or loss:					
Revenues					
Revenues from hospital operations		6,355,875	3,485,801	2,677,551	1,555,508
Dividend income	5	-	-	1,220,000	120,000
Other income		134,987	121,249	4,433	3,925
Total revenues		6,490,862	3,607,050	3,901,984	1,679,433
Expenses					
Cost of hospital operations		3,199,100	2,200,722	1,273,212	893,183
Administrative expenses		427,754	365,485	216,604	192,634
Total expenses		3,626,854	2,566,207	1,489,816	1,085,817
Operating profit		2,864,008	1,040,843	2,412,168	593,616
Finance income		3,866	733	9,063	12,548
Finance cost		(6,388)	(11,029)	(511)	(2,962)
Profit before income tax expenses		2,861,486	1,030,547	2,420,720	603,202
Income tax expenses		(566,555)	(205,768)	(238,988)	(94,845)
Profit for the period		2,294,931	824,779	2,181,732	508,357
Other comprehensive income:					
Other comprehensive income for the period			-	- -	
Total comprehensive income for the period		2,294,931	824,779	2,181,732	508,357

Statement of comprehensive income (continued)

For the six-month period ended 30 June 2022

(Unit: Thousand Baht, except earnings per share expressed in Baht)

	Consolidated fina	ncial statements	Separate financial statements		
	2022	2021	2022	2021	
Profit (loss) attributable to:					
Equity holders of the Company	2,234,633	827,866	2,181,732	508,357	
Non-controlling interests of the subsidiaries (loss)	60,298	(3,087)			
	2,294,931	824,779			
Total comprehensive income attributable to:					
Equity holders of the Company	2,234,633	827,866	2,181,732	508,357	
Non-controlling interests of the subsidiaries (loss)	60,298	(3,087)			
	2,294,931	824,779			
Basic earnings per share					
Profit attributable to equity holders of the Company					
(Baht per share)	0.2031	0.0753	0.1983	0.0462	
Weighted average number of ordinary shares					
(Thousand shares)	11,000,000	11,000,000	11,000,000	11,000,000	

Cash flow statement

For the six-month period ended 30 June 2022

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2022	2021	2022	2021
Cash flows from operating activities				
Profit before tax	2,861,486	1,030,547	2,420,720	603,202
Adjustments to reconcile profit before tax to net cash				
provided by (paid from) operating activities:				
Depreciation and amortisation	187,559	172,102	73,365	58,818
Reversal of allowance for expected credit losses	(17)	-	-	-
Loss on fair value adjustments of financial assets	-	1,292	-	-
Reduction of inventory to net realisable value	-	380	-	-
Increases in allowance for diminution in value				
of right-of-use assets	-	2,009	-	-
Loss (gain) on sales and write-offs of assets	3,044	(133)	89	(156)
Unrealised exchange losses	14,911	3,155	-	-
Increase in provision for long-term employee benefits	6,230	6,158	3,149	3,124
Dividend income	-	-	(1,220,000)	(120,000)
Finacial income	(3,866)	(733)	(9,063)	(12,548)
Interest expenses	6,388	11,029	511	2,962
Profit from operating activities before changes				
in operating assets and liabilities	3,075,735	1,225,806	1,268,771	535,402
Operating assets (increase) decrease				
Trade and other receivables	(87,942)	(36,578)	85,409	34,402
Accrued medical treatment income	(1,682,269)	(443,814)	(660,768)	(219,460)
Inventories	(20,337)	(37,361)	(22,115)	(30,733)
Other current assets	286,464	(2,138)	197,231	(2,041)
Other non-current assets	(9,380)	4,068	(9,318)	2,983
Operating liabilities increase (decrease)				
Trade and other payables	(9,171)	217,161	37,553	115,224
Other current liabilities	(47,409)	164,388	(254,131)	166,053
Cash paid for long-term employee benefits	(747)	(156)		(156)
Cash from operating activities	1,504,944	1,091,376	642,632	601,674
Cash paid for interest expenses	(5,105)	(9,911)	(86)	(2,679)
Cash paid for income tax	(776,710)	(131,853)	(361,548)	(69,414)
Net cash from operating activities	723,129	949,612	280,998	529,581

Cash flow statement (continued)

For the six-month period ended 30 June 2022

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2022	2021	2022	2021
Cash flows from investing activities				
Decrease in investments in other current financial assets, net	-	17,140	-	-
Dividend income from subsidiaries	-	-	1,220,000	120,000
Cash paid for investments in subsidiaries	-	-	-	(359,200)
Decrease in long-term loans to subsidiaries	-	-	136,500	51,048
Cash paid in advance for construction of buildings	(26,736)	(7,335)	-	(7,335)
Cash paid for acquisition and payment of				
accounts payable - fixed assets	(255,364)	(145,664)	(115,767)	(41,876)
Cash paid for acquisition of intangible assets	(2,003)	(2,414)	(664)	(1,401)
Proceed from sales of assets	522	4,931	566	8
Interest received	3,881	907	2,483	15,173
Net cash from (used in) investing activities	(279,700)	(132,435)	1,243,118	(223,583)
Cash flows from financing activities				
Increase (decrease) in short-term loans				
from financial institutions, net	(13,000)	161,500	-	130,000
Cash receipt from long-term loans	10,000	-	-	-
Repayment of long-term loans	(62,210)	(68,100)	-	-
Repayment of lease liabilities	(14,106)	(10,079)	(4,323)	(2,192)
Cash receipt from non-controlling interests of				
investments in subsidiaries	-	40,101	-	-
Dividend paid	(1,869,999)	(329,812)	(1,869,999)	(329,812)
Dividend paid by subsidiary to non-controlling interests	(2,351)	-	-	-
Net cash used in financing activities	(1,951,666)	(206,390)	(1,874,322)	(202,004)
Net increase (decrease) in cash and cash equivalents	(1,508,237)	610,787	(350,206)	103,994
Cash and cash equivalents at beginning of period	2,789,666	547,540	781,074	241,039
Cash and cash equivalents at end of period	1,281,429	1,158,327	430,868	345,033
Supplement cash flows information	-		-	
Non-cash transactions				
Transfer advance payment for construction to buildings	18,589	7,590	7,594	-
Acquisition of fixed assets which cash has not been paid	52,160	61,561	32,797	37,031
Increase in right-of-use assets and lease liabilities				
from additional lease agreements	18,681	13,824	4,719	7,504
Transfers right-of-use assets to property, plant and equipment	555	322	187	-

Chularat Hospital Public Company Limited and its subsidiaries Statement of changes in shareholders' equity

For the six-month period ended 30 June 2022

(Unit: Thousand Baht)

Consolidated financial statements

		Equity attri	butable to owners of the	e Company			
					_	Equity	
					Total equity	attributable to	
	Issued and				attributable to	non-controlling	
	paid-up		Retained	earnings	owners of	interests of	Total
	share capital	Share premium	Appropriated	Unappropriated	the Company	the subsidiaries	shareholders' equity
Balance as at 1 January 2021	1,100,000	1,146,085	110,000	1,668,388	4,024,473	168,708	4,193,181
Dividend paid (Note 9)	<u> </u>	-		(329,812)	(329,812)		(329,812)
Profit (loss) for the period	-	-	-	827,866	827,866	(3,087)	824,779
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	827,866	827,866	(3,087)	824,779
Increase in equity attributable to non-controlling							
interests of the subsidiaries from investment							
in subsidiaries	-	-	-	-	-	40,101	40,101
Balance as at 30 June 2021	1,100,000	1,146,085	110,000	2,166,442	4,522,527	205,722	4,728,249
	4 400 000	4 4 4 0 0 0 5	440.000	5 040 055	7 500 0 40	070.004	7.040.004
Balance as at 1 January 2022	1,100,000	1,146,085	110,000	5,212,855	7,568,940	272,024	7,840,964
Dividend paid (Note 9)	-	-	-	(1,869,999)	(1,869,999)	-	(1,869,999)
Dividends paid by subsidiary to non-controlling							
interests (Note 5)		<u>-</u>				(2,351)	(2,351)
Profit for the period	-	-	-	2,234,633	2,234,633	60,298	2,294,931
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-		2,234,633	2,234,633	60,298	2,294,931
Balance as at 30 June 2022	1,100,000	1,146,085	110,000	5,577,489	7,933,574	329,971	8,263,545

(Unaudited but reviewed)

Chularat Hospital Public Company Limited and its subsidiaries Statement of changes in shareholders' equity (continued) For the six-month period ended 30 June 2022

(Unit: Thousand Baht)

Separate financial statements

	Issued and paid-up		Retained	Total	
	share capital	Share premium	Appropriated	Unappropriated	shareholders' equity
Balance as at 1 January 2021	1,100,000	1,146,085	110,000	1,452,634	3,808,719
Dividend paid (Note 9)	-	-	-	(329,812)	(329,812)
Profit for the period	-	-	-	508,357	508,357
Other comprehensive income for the period	-	-	-	-	-
Total comprehensive income for the period	-	-	-	508,357	508,357
Balance as at 30 June 2021	1,100,000	1,146,085	110,000	1,631,179	3,987,264
Balance as at 1 January 2022	1,100,000	1,146,085	110,000	2,882,107	5,238,192
Dividend paid (Note 9)				(1,869,999)	(1,869,999)
Profit for the period	-	-	-	2,181,732	2,181,732
Other comprehensive income for the period	-	-	-	-	-
Total comprehensive income for the period				2,181,732	2,181,732
Balance as at 30 June 2022	1,100,000	1,146,085	110,000	3,193,840	5,549,925

Chularat Hospital Public Company Limited and its subsidiaries
Notes to interim consolidated financial statements
For the three-month and six-month periods ended 30 June 2022

1. General information

1.1 Corporate information

Chularat Hospital Public Company Limited ("the Company") is a public company incorporated and domiciled in Thailand. The Company is principally engaged in the operating of clinics and hospitals. The registered office of the Company is at 88/8-9, Teparak Km.15 Road, Tambol Bangpla, Amphur Bangplee, Samutprakarn. As at 30 June 2022, the Company and its subsidiaries totally have 14 branches of clinics and hospitals (31 December 2021: 14 branches).

1.2 Basis for the preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language financial statements.

1.3 Basis of consolidation

These interim consolidated financial statements include the financial statements of Chularat Hospital Public Company Limited ("the Company") and its subsidiaries ("the subsidiaries") (collectively as "the Group") and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2021.

1.4 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 December 2021.

The revised financial reporting standards which are effective for fiscal years beginning on or after 1 January 2022, do not have any significant impact on the Group's financial statements.

2. Related party transactions

During the period, the Group had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business. There were no significant changes in the transfer pricing policy of transactions with related parties during the current period.

Summaries significant business transactions with related parties are as follows:

(Unit: Million Baht)

	For the three-month periods ended 30 June				
	Consol	idated	Separate financial statements		
	financial st	tatements			
	2022	2021	2022	2021	
Transactions with subsidiaries					
(eliminated from the consolidated					
financial statements)					
Sales of medicine and supplies	-	-	29	1	
Purchases of medicine and supplies	-	-	7	-	
Laboratory service income	-	-	1	4	
Laboratory service expenses	-	-	1	-	
Rental income	-	-	1	1	
Interest income	-	-	3	6	
Purchases of equipment	_	-	1	1	

(Unit: Million Baht) For the six-month periods ended 30 June

	Consolidated		Separate		
	financial st	atements	financial statements		
	2022	2021	2022	2021	
Transactions with subsidiaries					
(eliminated from the consolidated					
financial statements)					
Sales of medicine and supplies	-	-	75	3	
Purchases of medicine and supplies	-	-	7	-	
Laboratory service income	-	-	5	14	
Laboratory service expenses	-	-	1	-	
Rental income	-	-	1	1	
Interest income	-	-	7	12	
Purchases of equipment	-	-	1	1	

As at 30 June 2022 and 31 December 2021, the balances of accounts between the Company and related parties are as follows:

			(Unit:	Thousand Baht)
	Consolidated		Separate	
	financial	statements	financial statements	
	30 June	31 December	30 June	31 December
	2022	2021	2022	2021
Trade and other receivables - related parties				
Subsidiaries		-	114,467	229,276
		-	114,467	229,276
Interest receivable from related parties				
Subsidiaries		<u>-</u>	75,416	68,836
		<u> </u>	75,416	68,836
Long-term loans to related parties				
Subsidiaries		<u> </u>	365,974	502,474
		<u> </u>	365,974	502,474
Trade and other payables - related parties				
Subsidiaries	-	-	10,091	4,859
Related company	445	642	423	620
	445	642	10,514	5,479

Long-term loans to related parties

The balance of loans between the Company and its subsidiaries and the movement are as follows:

(Unit: Thousand Baht)

	Separate financial statements					
	Balance as at	Increase	Decrease	Balance as at		
Loans to	31 December 2021	during the period	during the period	30 June 2022		
Chularat Phraek Sa Hospital Company						
Limited	153,555	-	-	153,555		
Chularat Arkanay Hospital Company						
Limited	315,319	-	(136,500)	178,819		
Shewarat Hospital Company Limited	33,600			33,600		
Total	502,474	-	(136,500)	365,974		

Directors and management's benefits

During the three-month and six-month periods ended 30 June 2022 and 2021, the Group had employee benefit expenses payable to their directors and management as below.

(Unit: Million Baht)

	For the three-month periods ended 30 June				
	Consol	idated	Separate		
	financial statements		financial statements		
	2022 2021		2022	2021	
Short-term employee benefits	10.2	11.3	4.0	5.1	
Total	10.2	11.3	4.0	5.1	

(Unit: Million Baht)

For the six-month periods ended 30 June

	Consolidated		Separate	
	financial statements		financial st	atements
	2022 2021		2022	2021
Short-term employee benefits	21.9	23.3	9.3	10.9
Total	21.9 23.3		9.3	10.9

Guarantee obligations with related parties

The Company has outstanding guarantee obligations with its subsidiaries, as described in Note 10.3 a) to the interim consolidated financial statements, with free of charge.

3. Trade and other receivables

(Unit: Thousand Baht) Consolidated Separate financial statements financial statements 30 June 31 December 31 December 30 June 2022 2021 2022 2021 Trade accounts receivable - related parties Age of outstanding debts by due date Past due up to 3 months 66,674 178,387 Total trade accounts receivable - related parties 66,674 178,387 Trade accounts receivable - unrelated parties Age of outstanding debts by due date Past due Up to 3 months 396,753 427,824 166,591 162,119 3 - 6 months 189,669 106,392 61,785 28,946 6 - 12 months 81,538 43,554 20,130 23,173 Over 12 months 39,728 35,232 21,546 19,087 Total 707,688 613,002 270,052 233,325 Less: Allowance for expected credit losses (20,595)(20,612)(7,574)(7,574)Total trade accounts receivable - unrelated parties, net 687,093 592,390 262,478 225,751 Total trade accounts receivable - net 687,093 329,152 404,138 592,390 Other receivables Other receivable - related parties 47,793 50,889 Other receivable - unrelated parties 17,133 23,892 13,763 21,090 Interest receivable - related parties 75,416 68,836 Total other receivables 17,133 23,892 136,972 140,815 Total trade and other receivables - net 704,226 616,282 466,124 544,953

4. Accrued medical treatment income

(Unit: Thousand Baht)

	Conso	lidated	Separate	
	financial statements		financial s	statements
	30 June	31 December	30 June	31 December
	2022	2021	2022	2021
Accrued medical treatment income from				
National Health Security Office	94,429	94,111	64,156	70,083
Accrued medical treatment income of chronic				
diseases from Social Security Office	307,931	180,283	84,789	49,817
Accrued medical treatment income provided				
to patients with severe diseases from				
Social Security Office	288,557	167,461	178,889	104,774
Other accrued income from Social Security				
Office	138,997	134,235	62,882	52,983
Accrued medical treatment income -				
Coronavirus Disease 2019	2,673,501	1,245,056	1,045,906	498,197
Total accrued medical treatment income	3,503,415	1,821,146	1,436,622	775,854
Less: Allowance for expected credit losses	(622)	(622)		
Total accrued medical treatment income - net	3,502,793	1,820,524	1,436,622	775,854

The Group is not able to determine the certain amount of medical treatment income that has not been collected from the National Health Security Office and Social Security Office. In this regard, the management of the Group makes an estimate of accrued income based on the amount of the latest actual collection together with the current circumstances. In addition, the Group's management makes an estimate of medical treatment income with respect to the Coronavirus Disease 2019 that has not been collected, by consideration the criteria, procedures and conditions set forth by the Ministry of Health.

The payment for the accrued medical treatment income is subject to the medical treatment payment policy of the relevant office. The management believes that the actual outcome will not significantly differ from the estimate.

As of 30 June 2022, most of the Group's accrued medical treatment income is not overdue more than 12 months, which is in accordance with reimbursement criteria, procedures and conditions of the relevant office.

5. Investments in subsidiaries

During the current period, there were no change in shareholding structure of the subsidiaries.

During the three-month and six-month periods ended 30 June 2022 and 2021, the Company received dividend from its subsidiaries as below.

(Unit: Thousand Baht)

Company's name	2022	2021
Convenience Hospital Company Limited	800,000	120,000
Bangpakong Vejchakij Company Limited	420,000	
	1,220,000	120,000

In the second quarter of 2022, Cholvaej Hospital Company Limited, which is a subsidiary of Bangpakong Vejchakij Company Limited, paid an interim dividend of Baht 3 per share, a total of Baht 120 million of which Baht 117.65 million and Baht 2.35 million were paid to Bangpakong Vejchakij Company Limited and non-controlling interests, respectively.

6. Short-term loans from financial institutions

Short-term loans from financial institutions are secured by the mortgage of land with structures thereon of the Group.

7. Long-term loans from financial institutions

Long-term loans from financial institutions are secured by the mortgage of the subsidiaries' land and structures thereon.

Movements in the long-term loans account during the six-month period ended 30 June 2022 are summarised below.

	(Unit: Thousand Baht)
	Consolidated
	financial statements
Balance as at 1 January 2022	410,547
Add: Increase during the period	10,000
Less: Payment during the period	(62,210)
Add: Unrealised gain on exchange rate	(23,606)
Balance as at 30 June 2022	334,731
Less: Current portion	(64,997)
Long-term loans, net of current portion	269,734

On 21 March 2022, Ruampat Mae Sot International Company Limited, its subsidiary, entered into a long-term loan agreement with a local financial institution in order to construction of the subsidiary's hospital, which have the credit facility of Baht 300 million. The loan carries interest at the minimum loan rate (MLR) minus 2.90 percent per annum and the repayment of principal is to be made on a monthly basis, from April 2024 to March 2032. The loan is secured by the mortgage of land with structures thereon and future structures of the subsidiary.

On 1 April 2022, Ruampat Chachoengsao Hospital Company Limited entered into a long-term loan agreement with a local financial institution to obtain the loan of USD 8.99 million for use in making repayment of the Baht loan according the above loan agreement. The loan carries interest at the rate of 4.432 percent per annum. The loan agreement is effective from 29 September 2023 and the term of the agreement is 8.5 years, due within March 2032. The loan is secured by the mortgage of land with structures thereon and future structures of the subsidiary.

The above loan agreements contain covenants and restrictions such as prohibitions on the subsidiary's incurring indebtedness or obligations, providing guarantees of loans, disposal of assets, reduction of capital or merger, and obligation to maintain certain financial ratios as specified in the agreements.

As at 30 June 2022, the long-term credit facilities of the subsidiary which have not yet been drawn down amounted to Baht 290 million (31 December 2021: None).

8. Segment information

The Group has two reportable segments that are hospital operations and other businesses that support hospital business including distribution of medical instruments. These two segments have similar economic characteristics. They both have common customer group, similar service provision methods and similar management. Its operations are carried on only in Thailand. Segment performance is measured based on operating profit or loss, on a basis consistent with that used to measure operating profit or loss in the financial statements. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain exclusively to the aforementioned reportable operating segment and geographical area.

9. Dividend paid

		Number of shares	Dividend	Total dividends
Dividends	Approved by	(Thousand shares)	per share (Baht)	(Thousand Baht)
Annual dividends for	Annual General Meeting			
2020	of the shareholders			
	on 23 April 2021	10,993,730	0.030	329,812
Total dividends for 2021				329,812
Annual dividends for	Annual General Meeting			
2021	of the shareholders			
	on 22 April 2022	10,999,995	0.170	1,869,999
Total dividends for 2022				1,869,999

10. Commitments and contingent liabilities

10.1 Capital commitments

a) The Group had capital commitments as follows:

			(Un	it: Million Baht)
	Consolidated		Separate	
	financial statements		financial	statements
	30 June 31 December		30 June	31 December
	2022	2021	2022	2021
Construction of buildings				
and building improvement	235	254	22	46
Acquisition of tools, equipment				
and motor vehicles	146	124	23	31

b) As at 30 June 2022, the Company had capital commitment amounting to Baht 237 million (31 December 2021: Baht 237 million) in respect of the uncalled portion of investment in the subsidiaries.

10.2 Service commitments

The Group has entered into service agreements. The terms of the agreements are generally between 1 and 3 years. Future minimum payments required under these service contracts were as follows:

			(U	nit: Million Baht)
	Consolidated		Separate	
	financial statements		financial	statements
	30 June 31 December		30 June	31 December
	2022	2021	2022	2021
Payable:				
In up to 1 year	47	38	21	24
In over 1 year and up to 3 years	13	10	12	7

10.3 Guarantees

- a) As at 30 June 2022, the Company has guaranteed bank credit facilities of two subsidiaries amounting to Baht 145 million (31 December 2021: Baht 145 million).
- b) There were outstanding bank guarantees issued by the banks on behalf of the Group, in respect of certain performance bonds as required in the normal course of business. The details of the letters of bank guarantee are as follows:

			(Unit: Million Baht)	
	Consolidated		Separate	
	financial statements		financial statements	
	30 June	31 December	30 June	31 December
	2022	2021	2022	2021
Guarantee contractual				
performance	141	180	70	60
Guarantee electricity use	11	19	4	12
Total	152	199	74	72

11. Financial instrument

Fair value of financial instrument

Since the majority of the Group's financial instruments are short-term in nature or carrying interest at rates close to the market interest rates, their fair value is not expected to be materially different from the amounts presented in the statement of financial position.

Fair value hierarchy

During the current period, there were no changes in the methods and the assumptions used to estimate the fair value of financial instruments and there were no transfers between the levels of the fair value hierarchy.

Derivatives not designated as hedging instruments

The Group uses cross currency interest rate swaps contract to manage some of its transaction exposures. The contract is entered into for periods consistent with foreign currency and interest rate exposure of the underlying transactions, generally 7 - 9 years.

12. Debentures

On 20 April 2017, the Annual General Meeting of the Company's shareholders passed the resolution to issue and offer up to Baht 2,000 million of debentures for sale, with a tenor of not more than 10 years. Further consideration and determination of significant conditions and details of the debentures relating to the financing of each issue of debentures are at the discretion of the Company's Board of Directors or other persons assigned by the Board of Directors.

13. Event after the reporting period

On 11 August 2022, a meeting of the Company's Board of Director No. 4/2022 approved for payment of an interim dividend to Baht 0.085 per share, or a total of Baht 935 million, from the profit for the six-month period ended 30 June 2022. This dividend will be paid on 9 September 2022.

14. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 11 August 2022.